U.S.-based AMAG Pharmaceuticals announced that it has agreed to purchase peer Perosphere Pharmaceuticals for up to $415 million.
AMAG said that the transaction will extend its pipeline, and especially its presence in hematology with Perosphere’s next-generation anticoagulant reversal candidate ciraparantag, PER977.
The company added that the purchase represents a great strategic fit and a unique opportunity to add a durable, innovative and differentiated mid-phase clinical asset to its portfolio.
The deal is expected to be completed in the first quarter of 2019, subject to customary closing conditions.